Lessons learnt: The reality of Inhala2on Gx Filings © Copyright Aedestra 2015 Philippe Rogueda 30 March 2015 Aedestra Ltd 1
Lessons learnt: The reality of Inhala2on Gx Filings
© Copyright Aedestra 2015
Philippe Rogueda 30 March 2015
Aedestra Ltd
1
Disclaimer The informa9on contained in this presenta9on is privileged. This presenta9on contains the personal opinions and thoughts of the presenter and may not be assumed to represent the opinion of Aedestra Ltd nor of any employer or company or learned society with whom the presenter might be or might have been associated. Aedestra Ltd makes no representa9ons to the accuracy of the informa9on contained therein. Aedestra Ltd declines any responsibility on the use of the informa9on contained in these slides. Aedestra Ltd does not recommend any course of ac9ons resul9ng directly or indirectly from the informa9on presented in these slides.
© Copyright Aedestra 2015 2
European aspira2ons
© Copyright Aedestra 2015 3
In vitro BE
PK BE
PD BE
The orderly stepwise approach of the European Union
European “perpetuum mobile”
© Copyright Aedestra 2015 4
In vitro BE
The PK study merry go round
PD BE PK BE X
Some famous UK Gx products
© Copyright Aedestra 2015 5
u Salbutamol: 3 pMDI 6 DPI
u Beclomethasone: 2 pMDI 4 DPI
u Most of these products were not filed as generics, but as brands. That in itself is quite revealing of the difficul9es in crea9ng generics in the inhala9on space.
u Only one product seems to have been filed on in vitro data in Europe … More about this a moment
u Formoterol: 1 pMDI 4 DPI
u Budesonide: 7 DPI
© Copyright Aedestra 2015
Salmeson -‐ Rolenium -‐ Elpen
Flu9casone pMDI -‐ Cipla
Airflusal -‐ Forspiro -‐ Sandoz
DuoResp -‐ Spiromax -‐ Teva
Formoterol DPI -‐ ELC
1
2
6
5
3
4
© Copyright Aedestra 2015 7
1. Rolenium: the challenger
Branded Gx – 2 blisters – 250/50 and 500/50 strengths. Filed in Greece 18 June 2009. First EU DCP approval 30 Nov 2011 RMS Sweden. No in vitro BE. PK BE. PD data.
© Copyright Aedestra 2015 8
Commercial claims – ACI data
Flu9casone FPF: Rolenium 16±6% Sere9de Diskus 23±13% ERS 2013 Abstract # 4967 Pub # P714
Elpen commercial lit.
© Copyright Aedestra 2015 9
Advanced Drug Delivery Reviews 75(2014) 18–31
Flow dependence of Flu2casone FPF
© Copyright Aedestra 2015 10
R. Price DDL 2013
PK study, 2 way crossover, single dose 500/50
© Copyright Aedestra 2015 11
Rolenium Approval History u 18 June 2009: Greece – What data was presented?
u 4 May 2011: DCP, RMS Sweden, CMS Bulg. Est. Lat. Lith. Lux. Rom. Slv. -‐No In Vitro BE
-‐PK efficacy 500/50, with charcoal, 60 Healthy subj., extrapolated to 250/50. -‐No PK safety, in vitro bioavailability knowledge sufficient. -‐2 informa9ve PD studies (500/50 & 250/50), FEV1, n=28
u 30 Nov 2011: DCP, RMS Sweden, CMS Cze. Ge. Hu. Icl. It. Pol. Slk.
-‐Same as 4 May 2011
u 13 March 2013: DCP, RMS Sweden, CMS Fl. Fr. No. Pol. DCP, RMS Sweden, CMS Au. Bel. Dk. Ir. Nl. -‐2011 + PK safety 250/50, without charcoal, Asthma pa9ents
2 PK, 2 PD studies acknowledged Not approved in: France, UK, Spain
© Copyright Aedestra 2015 12
2. Flu2casone pMDi: luck incarnate? u Flu9casone pMDI CIPLA agains Flixo9de Evohaler. u 2 strengths approved 11 June 2013, RMS Sweden, CMS Ge, Sp.
u 2nd approval: 25 Sept 14, RMS Sweden, CMS Fl, Ge, Hu, It, No, Sp
u No in vitro BE, 2 PK studies acknowledged.
u PK studies WO charcoal: -‐32 subjects -‐28 subjects with spacer
How many studies were necessary to fine tune this formula2on?
© Copyright Aedestra 2015 13
3. Airflusal: normalised data
u Flu9casone + Salmeterol DPI
u 2 Strengths approved 500/50 & 250/50
u No in vitro match
u 3 PK (W/Wo Charcoal), 2 PD (one PIF)
u PD studies (n=555) and PIF study (n=60)
u Major point of applica9on: FPD of Flu9casone was normalised to yield an IVIV correla9on with Cmax, and achieve Cmax BE
© Copyright Aedestra 2015 14
AUC0-‐tpg*h/ml Cmax pg/ml
Test 328.57 ± 109.00 297.50 ± 111.29
Reference 282.11 ± 90.83 265.69 ± 84.21
Normalised Ra9o (90%CI)
1.1592 (1.1243-‐1.1952)
1.1041 (1.0574-‐1.1528)
Natural Ra9o 1.1647 1.1197
AUC0-‐tpg*h/ml Cmax pg/ml
Test 1083.11 ± 311.76 148.03 ± 45.16
Reference 1166.84 ± 260.88 176.53 ± 49.99
Normalised Ra9o(90%CI)
0.9129 (0.8791-‐0.9479)
0.8340 (0.8022-‐0.8671)
Natural Ra9o 0.9282 0.8386
u Flu9casone, PK, 2 x 50/500, n=59.
u Salmeterol, PK, 2 x 50/500, n=59.
© Copyright Aedestra 2015 15
4. DuoResp: 11 clinical studies
2 strengths, 11 clinical studies, 628 volunteers, 77 children, 20 years in the making
© Copyright Aedestra 2015 16
Centralised procedure: seal of quality?
u Dossier received 29 Jan 2013, posi9ve opinion 20 Feb 2014
u 3 strengths submired, 2 approved: 160/4.5 & 320/9
u Asthma and COPD
u Children and adolescent excluded
u 8 scien9fic mee9ngs: 24 Sept, 6 Nov, 8 Dec 2009; 9 April, 22 April, 18 Nov 2010; 22 Sept 2011; 16 Feb 2012
u No in-‐vitro BE
u 9 PK studies submired (3 strengths) and 2 PD (one safety study in children)
© Copyright Aedestra 2015 17
In vitro data – Middle strength
DUORESP SYMBICORT T/R L/min 40 60 90 40 60 90 40 60 90 % LC
BUDESONIDE TD 94.78 97.08 99.94 70.73 85.52 93.94 1.34 1.14 1.06 IP+PS 59.25 53.81 50.02 37.16 35.47 37.73 1.59 1.52 1.33 FPD 31.07 38.39 44.21 29.19 45.23 51.47 1.06 0.85 0.86 MMAD 2.41 2.2 2.09 2.58 2.25 2.01 0.93 0.98 1.04 GSD 1.86 1.94 1.98 1.78 1.83 1.95 1.04 1.06 1.02
FORMOTEROL TD 88.04 91.15 96.76 69.9 84.53 93.86 1.26 1.08 1.03 IP+PS 57.27 51.85 49.29 37.43 35.38 38.61 1.53 1.47 1.28 FPD 27.54 35.51 42.44 27.93 43.95 50.19 0.99 0.81 0.85 MMAD 2.39 2.18 2.11 2.63 2.3 2.08 0.91 0.95 1.01 GSD 1.86 1.9 2.01 1.78 1.84 1.94 1.04 1.03 1.04
© Copyright Aedestra 2015 18
Spiromax PIF studies
© Copyright Aedestra 2015 19
5. Formoterol DPI: a rare case of in vitro filing
u RMS Sweden, CMS France
u Authorisa9on granted: 12 Dec. 2014
© Copyright Aedestra 2015 20
Formoterol DPI: a rare case of in vitro filing
u Ref: Foradil, Aerolizer u In vitro BE only
Same device design Same cri9cal dimension Same handling Same device resistance
u Special request: PIF and FIVC study on 20 subjects REF & TEST
REF TEST FIVC (L) 2.2 2.1 PIF (L/min) 101.23 102.65
u Let’s study its in vitro performance!
Lessons learnt
© Copyright Aedestra 2015 21
Products In Vitro BE PK/PD studies PIF studies
Rolenium ✗ 4 ✓ Seroflo pMDI ✗ 2 !! ✓ Airflusal ✗ 5 ✓ DuoResp ✗ 11 ✓ Formoterol DPI ✓ ✗ ✓
When mul9ple strengths are available, the lower strength seems impossible to match and file.
Lessons learnt
© Copyright Aedestra 2015
u In vitro filing is possible in the EU. It is the excep9on rather than the norm.
u In vitro filing requires same device, formula9on, API, groupings. Further requirements: PIF study, Handling studies, knowledge of bioavailability of API/Formula9on. A stage by stage match is difficult, groupings will be accepted when jus9fied.
u Some countries are more recep9ve to in vitro filing than others.
u Most products will be approved aver PK studies. Study the reference product in depth. How many PK studies will you conduct?
u Do not assume a linear development: in vitro followed by PK. This is a very naïve approach.
u The variety of PK studies presented and their jus9fica9ons show the complexity of the inhala9on field, and the recep9veness of regulatory authori9es.
22
The most likely filing scenario
© Copyright Aedestra 2015 23
In vitro BE
PK BE
+ Aim to achieve PK In Vitro BE is nigh impossible
© Copyright Aedestra 2015
www.inhalationasia.org
Follow us on
24
With compliments
AEDESTRA Ltd
© Copyright Aedestra 2015 25